**Specifications Table**TableSubject area*Biochemistry and Molecular Biology*More specific subject area*Lipidomics*Type of data*Tables*How data was acquired*Ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UPLC/qTOF-MS)*Data format*Analysed*Experimental factors*Analysis of triacylglycerol and phosphatidylcholine species extracted from MDA-MB-231 cells treated with exogenous docosahexaenoic acid, human group X secreted phospholipase A*~*2*~*and depleted in adipose triglyceride lipase*Experimental features*Lipidomic analyses of cellular lipids by UPLC/qTOF-MS*Data source location*Not applicable*Data accessibility*Provided with this article*

**Value of the data**•This lipidomic data provides information on the lipid composition of Ras-driven aggressive MDA-MB-231 breast cancer cells exposed to nutrient stress [@bib1].•It identifies changes in membrane and lipid droplet (LD) composition induced by alterations in LD biogenesis and lipolysis and associated with protection from the lipotoxicity of polyunsaturated fatty acids.•The data describes triacylglycerol (TAG) and phosphatidylcholine (PC) remodelling mediated by human group X secreted phospholipase A~2~ (sPLA~2~) in docosahexaenoic acid (DHA)-treated and adipose triglyceride lipase (ATGL)-depleted breast cancer cells.•The data describes changes in lipid composition following inhibition of TAG lipolysis and LD breakdown by ATGL depletion in DHA-treated breast cancer cells.•The data will foster further examination of the role of LDs in the resistance of cancer cells to nutrient and lipotoxic stress.

1. Data {#s0005}
=======

In order to determine the changes in TAG composition of LDs and in the profile of cellular PC associated with sPLA~2~-induced protection of breast cancer cells from DHA lipotoxicity, we extracted lipids from MDA-MB-231 cells treated with 100 µM DHA and a combination of 100 µM DHA and 10 nM sPLA~2~ and performed lipidomic analyses [@bib1]. The TAG and PC profiles determined are presented in [Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}, respectively.Table 1TAG profiles of control, DHA- and sPLA~2~-treated MDA-MB-231 breast cancer cells.Table 1:**TAG composition (% of total)**[a](#tbl1fna){ref-type="table-fn"}**TAG species**[b](#tbl1fnb){ref-type="table-fn"}Untreated[c](#tbl1fnc){ref-type="table-fn"}DHADHA+sPLA~2~**46:0**0.36 ± 0.03n.d.0.05 ± 0.02**48:0**1.2 ± 0.10.07 ± 0.010.16 ± 0.03**48:1**1.3 ± 0.10.12 ± 0.010.2 ± 0.1**50:0**3.3 ± 0.40.14 ± 0.020.4 ± 0.1**50:1**5.5 ± 0.10.4 ± 0.11.0 ± 0.2**50:2**2.3 ± 0.20.2 ± 0.10.6 ± 0.1**52:0**6.0 ± 1.00.26 ± 0.040.8 ± 0.1**52:1**11.3 ± 0.31.1 ± 0.11.8 ± 0.3**52:2**8.1 ± 0.21.0 ± 0.12.0 ± 1.0**52:3**3.0 ± 0.30.44 ± 0.030.9 ± 0.2**52:4**0.64 ± 0.030.15 ± 0.010.3 ± 0.1**54:0**1.8 ± 0.10.06 ± 0.010.17 ± 0.01**54:1**8.2 ± 0.30.72 ± 0.021.3 ± 0.2**54:2**6.0 ± 1.00.7 ± 0.11.3 ± 0.1**54:3**5.0 ± 1.00.8 ± 0.11.7 ± 0.4**54:4**2.9 ± 0.10.6 ± 0.11.1 ± 0.2**54:5**2.4 ± 0.1n.d.n.d.**54:6**1.2 ± 0.12.6 ± 0.42.6 ± 0.2**54:7**0.22 ± 0.031.1 ± 0.11.26 ± 0.03**56:0**1.0 ± 0.1n.d.0.10 ± 0.01**56:1**1.85 ± 0.020.16 ± 0.030.23 ± 0.03**56:2**1.8 ± 0.10.26 ± 0.020.4 ± 0.1**56:3**1.6 ± 0.10.28 ± 0.020.43 ± 0.03**56:6**4.1 ± 0.33.0 ± 1.05.4 ± 0.4**56:7**1.2 ± 0.24.4 ± 0.36.7 ± 0.1**58:1**1.9 ± 0.10.120 ± 0.0040.25 ± 0.01**58:2**1.19 ± 0.020.12 ± 0.020.23 ± 0.03**58:3**0.6 ± 0.1n.d.0.17 ± 0.02**58:5**1.6 ± 0.20.17 ± 0.020.7 ± 0.1**58:6**2.5 ± 0.2n.d.n.d.**58:7**1.7 ± 0.24.6 ± 0.47.2 ± 0.2**58:8**0.5 ± 0.12.8 ± 0.24.8 ± 0.1**58:9**0.12 ± 0.021.00 ± 0.031.7 ± 0.1**58:10**n.d.0.83 ± 0.021.3 ± 0.1**58:11**0.02 ± 0.010.91 ± 0.041.1 ± 0.1**58:12**0.03 ± 0.023.1 ± 0.31.9 ± 0.2**60:1**2.21 ± 0.04n.d.0.31 ± 0.04**60:2**1.47 ± 0.030.146 ± 0.0020.31 ± 0.02**60:3**0.5 ± 0.10.04 ± 0.010.16 ± 0.01**60:4**0.32 ± 0.040.05 ± 0.020.12 ± 0.02**60:10**0.07 ± 0.011.91 ± 0.023.0 ± 0.2**60:12**0.8 ± 0.118.0 ± 1.014.1 ± 1.1**60:13**n.d.3.4 ± 0.11.6 ± 0.3**62:1**0.9 ± 0.1n.d.n.d.**62:2**0.79 ± 0.030.05 ± 0.010.163 ± 0.003**62:3**0.40 ± 0.020.027 ± 0.0020.112 ± 0.004**62:11**n.d.1.1 ± 0.21.5 ± 0.2**62:12**0.5 ± 0.19.0 ± 0.39.0 ± 1.0**62:13**0.8 ± 0.115.0 ± 1.014.0 ± 1.0**62:14**n.d.2.9 ± 0.12.2 ± 0.2**66:18**0.3 ± 0.115.0 ± 2.07.0 ± 1.0[^1][^2][^3]Table 2PC profiles of control, DHA- and sPLA~2~-treated MDA-MB-231 breast cancer cells.Table 2:**PC composition (% of total)**[a](#tbl2fna){ref-type="table-fn"}**PC species**[b](#tbl2fnb){ref-type="table-fn"}Untreated[c](#tbl2fnc){ref-type="table-fn"}DHADHA+sPLA~2~**30:0**2.7 ± 0.24.8 ± 0.33.2 ± 0.2**30:1**2.3 ± 0.22.3 ± 0.12.4 ± 0.2**32:0**5.0 ± 0.121.0 ± 0.313.0 ± 1.0**32:1**9.0 ± 1.07.0 ± 1.06.1 ± 0.3**34:1**28.0 ± 1.017.0 ± 1.023.0 ± 1.0**34:2**5.3 ± 0.32.9 ± 0.23.1 ± 0.1**34:3**0.26 ± 0.011.1 ± 0.10.6 ± 0.1**36:0**0.47 ± 0.040.31 ± 0.020.6 ± 0.1**36:1**21.0 ± 1.07.9 ± 0.315.0 ± 1.0**36:2**13.0 ± 0.14.9 ± 0.17.6 ± 0.2**36:4**2.46 ± 0.042.65 ± 0.012.9 ± 0.1**36:5**0.48 ± 0.041.4 ± 0.10.9 ± 0.1**36:6**0.07 ± 0.011.0 ± 0.20.29 ± 0.01**38:3**1.9 ± 0.11.1 ± 0.11.5 ± 0.1**38:4**3.0 ± 0.12.6 ± 0.33.4 ± 0.4**38:5**2.0 ± 0.32.7 ± 0.23.1 ± 0.1**38:6**1.1 ± 0.19.0 ± 1.06.0 ± 1.0**40:6**1.5 ± 0.17.0 ± 1.06.0 ± 1.0**40:7**0.5 ± 0.13.1 ± 0.32.0 ± 0.3[^4][^5][^6]

In order to determine the changes in TAG composition of LDs and in the profile of cellular PC in ATGL-depleted breast cancer cells, MDA-MB-231 cells were transfected with ATGL-targeting siRNA or non-targeting scrambled siRNA (SCR). In addition, cells were treated with 10 nM sPLA~2~ and 100 µM DHA. Lipids were extracted and lipidomic analyses performed. The data presented includes the detected TAG ([Table 3](#t0015){ref-type="table"}) and PC species ([Table 4](#t0020){ref-type="table"}) in control (SCR) and ATGL-depleted MDA-MB-231 breast cancer cells (siATGL), either untreated or treated with exogenous DHA, sPLA~2~ or both.Table 3TAG profiles of MDA-MB-231 breast cancer cells depleted in ATGL and treated with exogenous DHA, sPLA~2~ or both.Table 3:**TAG composition (% of total)**[a](#tbl3fna){ref-type="table-fn"}**TAG species**[b](#tbl3fnb){ref-type="table-fn"}SCR[c](#tbl3fnc){ref-type="table-fn"}siATGLSCR+DHAsiATGL+DHASCR+DHA+sPLA~2~siATGL+DHA+sPLA~2~**46:0**0.30 ± 0.030.42 ± 0.020.031 ± 0.0030.05 ± 0.010.03 ± 0.010.03 ± 0.01**48:0**1.3 ± 0.11.9 ± 0.10.11 ± 0.020.16 ± 0.010.08 ± 0.010.14 ± 0.01**48:1**1.19 ± 0.021.5 ± 0.10.16 ± 0.020.26 ± 0.040.15 ± 0.030.17 ± 0.03**50:0**3.8 ± 0.35.41 ± 0.030.3 ± 0.10.5 ± 0.10.2 ± 0.10.5 ± 0.1**50:1**5.1 ± 0.26.8 ± 0.10.5 ± 0.11.1 ± 0.20.6 ± 0.10.7 ± 0.1**50:2**1.94 ± 0.042.4 ± 0.20.3 ± 0.10.6 ± 0.10.3 ± 0.10.3 ± 0.1**52:0**6.3 ± 0.47.9 ± 0.20.5 ± 0.10.9 ± 0.10.4 ± 0.10.75 ± 0.02**52:1**11.0 ± 1.012.0 ± 1.01.1 ± 0.22.2 ± 0.31.1 ± 0.21.6 ± 0.1**52:2**8.0 ± 1.08.9 ± 0.41.4 ± 0.12.1 ± 0.31.3 ± 0.21.4 ± 0.2**52:3**2.3 ± 0.22.7 ± 0.20.6 ± 0.10.7 ± 0.10.5 ± 0.10.4 ± 0.1**52:4**0.68 ± 0.030.7 ± 0.10.20 ± 0.030.21 ± 0.020.21 ± 0.030.19 ± 0.02**54:0**1.7 ± 0.21.75 ± 0.030.09 ± 0.010.2 ± 0.10.07 ± 0.010.1327 ± 0.0002**54:1**8.1 ± 0.48.0 ± 1.00.7 ± 0.11.3 ± 0.20.7 ± 0.11.2 ± 0.2**54:2**5.5 ± 0.35.4 ± 0.20.6 ± 0.11.3 ± 0.20.9 ± 0.11.02 ± 0.01**54:3**5.0 ± 1.05.0 ± 1.01.1 ± 0.11.5 ± 0.21.2 ± 0.10.98 ± 0.01**54:4**2.5 ± 0.22.3 ± 0.10.6 ± 0.10.7 ± 0.10.8 ± 0.10.7 ± 0.1**54:5**2.1 ± 0.041.7 ± 0.1n.d.n.d.n.d.n.d.**54:6**1.4 ± 0.21.11 ± 0.042.5 ± 0.42.9 ± 0.32.4 ± 0.42.3 ± 0.2**54:7**0.21 ± 0.030.16 ± 0.021.0 ± 0.11.1 ± 0.11.1 ± 0.11.2 ± 0.1**56:0**1.0 ± 0.11.10 ± 0.020.06 ± 0.010.11 ± 0.04n.d.0.11 ± 0.02**56:1**2.0 ± 0.11.6 ± 0.10.14 ± 0.010.25 ± 0.030.12 ± 0.020.169 ± 0.004**56:2**1.9 ± 0.11.7 ± 0.10.23 ± 0.020.40 ± 0.10.23 ± 0.030.25 ± 0.02**56:3**1.50 ± 0.031.28 ± 0.030.20 ± 0.030.34 ± 0.040.32 ± 0.040.30 ± 0.01**56:6**3.9 ± 0.42.4 ± 0.044.0 ± 1.03.6 ± 0.45.0 ± 1.04.7 ± 0.3**56:7**1.7 ± 0.31.1 ± 0.15.0 ± 1.04.6 ± 0.36.9 ± 0.46.3 ± 0.4**58:1**1.91 ± 0.021.68 ± 0.040.11 ± 0.020.21 ± 0.040.13 ± 0.020.22 ± 0.04**58:2**1.2 ± 0.11.02 ± 0.010.12 ± 0.010.20 ± 0.020.12 ± 0.020.13 ± 0.01**58:3**0.62 ± 0.040.51 ± 0.030.06 ± 0.010.11 ± 0.010.11 ± 0.020.14 ± 0.04**58:5**1.7 ± 0.20.8 ± 0.10.3 ± 0.10.26 ± 0.020.7 ± 0.2n.d.**58:6**3.0 ± 0.41.9 ± 0.3n.d.n.d.n.d.n.d.**58:7**2.1 ± 0.31.7 ± 0.44.9 ± 0.44.9 ± 0.27.0 ± 1.06.9 ± 0.3**58:8**0.9 ± 0.10.6 ± 0.23.4 ± 0.43.4 ± 0.25.2 ± 0.24.9 ± 0.1**58:9**0.2 ± 0.10.2 ± 0.11.0 ± 0.10.92 ± 0.011.8 ± 0.11.7 ± 0.1**58:10**n.d.0.07 ± 0.030.82 ± 0.010.78 ± 0.021.267 ± 0.0021.23 ± 0.01**58:11**n.d.n.d.0.9 ± 0.10.88 ± 0.031.1 ± 0.11.2 ± 0.1**58:12**n.d.0.03 ± 0.012.7 ± 0.42.9 ± 0.32.0 ± 0.42.1 ± 0.1**60:1**2.3 ± 0.11.85 ± 0.020.13 ± 0.040.22 ± 0.030.15 ± 0.030.26 ± 0.03**60:2**1.50 ± 0.021.21 ± 0.020.14 ± 0.010.20 ± 0.020.16 ± 0.020.21 ± 0.04**60:3**0.60 ± 0.020.47 ± 0.020.05 ± 0.010.10 ± 0.020.09 ± 0.010.10 ± 0.02**60:4**0.4 ± 0.10.3 ± 0.10n.d.0.05 ± 0.010.09 ± 0.020.08 ± 0.01**60:10**0.1 ± 0.10.11 ± 0.041.9 ± 0.11.76 ± 0.013.1 ± 0.23.2 ± 0.1**60:12**1.1 ± 0.40.45 ± 0.0318.7 ± 0.318.0 ± 1.015.0 ± 1.016.0 ± 0.4**60:13**0.1 ± 0.10.062 ± 0.0043.0 ± 0.43.1 ± 0.12.0 ± 1.02.5 ± 0.1**62:1**1.0 ± 0.10.76 ± 0.03n.d.0.08 ± 0.01n.d.0.10 ± 0.01**62:2**0.9 ± 0.10.620 ± 0.0030.06 ± 0.020.08 ± 0.010.08 ± 0.020.12 ± 0.01**62:3**0.43 ± 0.020.31 ± 0.010.04 ± 0.010.050 ± 0.0040.07 ± 0.020.07 ± 0.01**62:11**n.d.0.04 ± 0.011.0 ± 0.1n.d.1.0 ± 0.11.2 ± 0.1**62:12**0.32 ± 0.040.3 ± 0.18.7 ± 0.26.6 ± 0.48.2 ± 0.17.0 ± 1.0**62:13**0.5 ± 0.20.43 ± 0.0117.3 ± 1.314.6 ± 1.115.59 ± 0.0215.0 ± 1.0**62:14**n.d.n.d.2.7 ± 0.42.6 ± 0.22.2 ± 0.42.4 ± 0.2**66:18**0.18 ± 0.040.18 ± 0.0112.3 ± 2.211.2 ± 1.47.0 ± 2.07.0 ± 1.0[^7][^8][^9]Table 4PC profiles of MDA-MB-231 breast cancer cells depleted in ATGL and treated with exogenous DHA, sPLA~2~ or both.Table 4:**PC composition (% of total)**[a](#tbl4fna){ref-type="table-fn"}**PC species**[b](#tbl4fnb){ref-type="table-fn"}SCR[c](#tbl4fnc){ref-type="table-fn"}siATGLSCR+DHAsiATGL+DHASCR+DHA+sPLA~2~siATGL+DHA+sPLA~2~**30:0**2.6 ± 0.32.7 ± 0.24.3 ± 0.15.7 ± 0.22.8 ± 0.14.7 ± 0.4**30:1**1.9 ± 0.32.2 ± 0.21.88 ± 0.042.44 ± 0.021.8 ± 0.12.3 ± 0.1**32:0**5.3 ± 0.25.3 ± 0.221.0 ± 1.025.0 ± 1.012.0 ± 1.012.2 ± 1.1**32:1**9.0 ± 1.09.5 ± 0.46.6 ± 0.27.3 ± 0.25.8 ± 0.16.3 ± 0.2**34:1**28.0 ± 1.028.8 ± 1.419.0 ± 1.018.0 ± 1.025.0 ± 1.021.2 ± 0.2**34:2**5.4 ± 0.24.9 ± 0.43.1 ± 0.12.9 ± 0.13.2 ± 0.12.6 ± 0.2**34:3**0.26 ± 0.020.28 ± 0.011.12 ± 0.011.2 ± 0.10.58 ± 0.030.6 ± 0.1**36:0**0.38 ± 0.010.5 ± 0.10.321 ± 0.0010.29 ± 0.020.51 ± 0.030.5 ± 0.1**36:1**20.0 ± 1.021.8 ± 1.49.0 ± 0.16.0 ± 1.015.0 ± 1.013.6 ± 1.1**36:2**13.4 ± 0.312.8 ± 0.35.8 ± 0.14.3 ± 0.39.0 ± 1.06.3 ± 0.3**36:4**2.4 ± 0.12.4 ± 0.12.6 ± 0.12.8 ± 0.12.9 ± 0.22.8 ± 0.1**36:5**0.5 ± 0.10.26 ± 0.021.31 ± 0.031.8 ± 0.10.9 ± 0.11.52 ± 0.02**36:6**0.11 ± 0.020.04 ± 0.010.8 ± 0.10.8 ± 0.10.4 ± 0.10.39 ± 0.02**38:3**1.8 ± 0.11.6 ± 0.11.05 ± 0.010.8 ± 0.11.5 ± 0.11.33 ± 0.03**38:4**2.8 ± 0.42.4 ± 0.22.5 ± 0.11.9 ± 0.13.1 ± 0.23.0 ± 0.1**38:5**2.0 ± 1.01.3 ± 0.12.4 ± 0.41.9 ± 0.23.2 ± 0.23.1 ± 0.3**38:6**1.7 ± 0.30.8 ± 0.18.0 ± 1.09.0 ± 1.06.0 ± 1.07.9 ± 0.3**40:6**1.5 ± 0.21.2 ± 0.16.0 ± 1.06.0 ± 1.05. 0 ± 1.07.8 ± 0.3**40:7**1.0 ± 0.10.31 ± 0.013.0 ± 0.12.3 ± 0.22.5 ± 0.22.0 ± 0.1[^10][^11][^12]

2. Experimental design, materials and methods {#s0010}
=============================================

2.1. Materials {#s0015}
--------------

Breast cancer cells (MDA-MB-231) and culture medium (RPMI-1640) were obtained from ATCC (USA), fetal bovine serum (FBS), Dulbecco\'s phosphate-buffered saline (DPBS), TrypLE Select and Opti-MEM from Life Technologies (USA). Docosahexaenoic acid (DHA) was from Cayman Chemical (USA), Lipofectamine RNAiMAX from Thermo Fisher Scientific (USA). Human ATGL-targeting siRNAs and Allstars Negative Control siRNA were from Qiagen (Germany). The recombinant wild-type human group X sPLA~2~ was prepared as described previously [@bib2], [@bib3], [@bib4]. All other chemicals were of at least analytical grade and purchased from Sigma-Aldrich (USA) or Serva (Germany).

2.2. Cell culture and treatment {#s0020}
-------------------------------

MDA-MB-231 cells were cultured in RPMI-1640 medium in the presence of 10% FBS. Adherent cells were detached using TrypLE Select. Aliquots of stock solutions of DHA in absolute ethanol were stored under argon at −80 °C. Prior to addition to cell culture, DHA was incubated in complete medium for 1 h at room temperature. Cells were seeded in complete medium in 6-well plates at 3 × 10^5^ cells/well. ATGL silencing was performed by reverse transfection at the time of seeding using a 20 nM mixture of two validated siRNAs targeted at ATGL (Qiagen) or 20 nM Allstars Negative Control siRNA (Qiagen). Transfection complexes were generated using 7.5 µl/well of Lipofectamine RNAiMAX and Opti-MEM medium. Reverse transfection was performed according to manufacturer\'s instructions. Cells were left to attach for 24 h and treated with 10 nM sPLA~2~ and 100 µM DHA for the following 48 h.

2.3. Lipidomic analyses of triacylglycerol and phospholipid species {#s0025}
-------------------------------------------------------------------

Culture plates were put on ice, the cells washed twice with ice-cold DPBS, collected by scraping in 300 µl lysis buffer (20 mM Tris--HCl, pH 7.4, 2 mM EDTA, 2 µl Halt Protease Inhibitor Cocktail, Thermo Scientific, USA), centrifuged at 4 °C (1000 *g*, 10 min), the pellet resuspended in 150 µl lysis buffer and sonicated on ice. Aliquots of 10 µl were taken for total protein determination using the Pierce 660 nm Protein Assay (Thermo Scientific, USA). Total lipids were extracted twice using chloroform/methanol/water (2/1/0.6, v/v/v) containing 500 pmol butylated hydroxytoluene, 1% acetic acid, and 100 pmol of internal standards (ISTD, 17:0-17:0 PC, 17:0-17:0 PE, 17:0-17:0-17:0 TAG, 17:0 LPC, Avanti Polar Lipids) per sample. Extraction was performed under constant shaking for 60 min at room temperature (RT). After centrifugation at 1000 × *g* for 15 min at RT the lower organic phase was collected, 2.5 ml chloroform added to the remaining aqueous phase and the second extraction performed as described above. Combined organic phases of the double-extraction were dried under a stream of nitrogen and dissolved in 150 µl 2-propanol/chloroform/methanol (7/2/1, v/v/v) for UPLC-qTOF analysis. Chromatographic separation was modified after Knittelfelder et al. [@bib5] using an AQUITY-UPLC system (Waters Corporation), equipped with an ACQUITY BEH C18 column (2.1 × 50 mm, 1.7 µm; Waters Corporation). A SYNAPT™G1 qTOF HD mass spectrometer (Waters Corporation) equipped with an ESI source was used for detection. Data acquisition was done by the MassLynx 4.1 software (Waters Corporation) and lipid classes were analysed with the "Lipid Data Analyzer 1.6.2" software [@bib6]. Data were normalised for recovery and extraction- and ionization efficacy using ISTDs.

2.4. Data handling {#s0030}
------------------

The acquired lipidomic data was normalised to total cellular protein. The values are presented as mean percentages of each species per total detected species in each sample with standard errors of the mean (SEM) of three independent experiments.
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[^1]: TAG composition data is presented as mean percentages of each species per total detected species and normalised to total cellular protein.

[^2]: TAG species are described based on the number of carbon atoms and double bonds.

[^3]: MDA-MB-231 cells were treated with 100 µM DHA and 10 nM sPLA~2~ in complete medium for 48 h and cell lysates were collected for UPLC/MS analysis. Values are means ± SEM of three independent experiments; n.d., not determined.

[^4]: PC composition data is presented as mean percentages of each species per total detected species and normalised to total cellular protein.

[^5]: PC species are described based on the number of carbon atoms and double bonds.

[^6]: MDA-MB-231 cells were treated with 100 µM DHA and 10 nM sPLA~2~ in complete medium for 48 h and cell lysates were collected for UPLC/MS analysis. Values are means ± SEM of three independent experiments; n.d., not determined.

[^7]: The lipidomic data is presented as mean percentages of each species per total detected species and normalised to total cellular protein.

[^8]: TAG species are presented according to the number of carbon atoms and double bonds.

[^9]: MDA-MB-231 cells were reverse transfected with ATGL-targeting siRNA (siATGL) or non-targeting scrambled siRNA (SCR) and treated with 100 µM DHA and 10 nM sPLA~2~ in complete medium for 48 h. Cell lysates were collected for UPLC/MS analysis. Values are means ± SEM of three independent experiments; n.d., not determined.

[^10]: The lipidomic data is presented as mean percentages of each species per total detected species and normalised to total cellular protein.

[^11]: PC species are presented according to the number of carbon atoms and double bonds.

[^12]: MDA-MB-231 cells were reverse transfected with ATGL-targeting siRNA (siATGL) or non-targeting scrambled siRNA (SCR) and treated with 100 µM DHA and 10 nM sPLA~2~ in complete medium for 48 h. Cell lysates were collected for UPLC/MS analysis. Values on the graphs are means ± SEM of three independent experiments; n.d., not determined.
